EMA Panel Recommends Ibalizumab for Multidrug-Resistant HIV-1 EMA Panel Recommends Ibalizumab for Multidrug-Resistant HIV-1

A European Medicines Agency advisory panel recommended marketing authorization for ibalizumab (Trogarzo, Theratechnologies International) for the treatment of patients with multidrug-resistant HIV-1 infection.International Approvals
Source: Medscape Med Students Headlines - Category: Universities & Medical Training Tags: HIV/AIDS News Alert Source Type: news

Related Links:

Background: Global increase of people infected with HIV (PIH) is causing changes in tuberculosis (TB) clinical and epidemiological data. HIV infection increases up to 20 times the chance of progression from latent infection to active forms of TB.Purpose: The paper aims to assess patients with TB-HIV coinfection in Olt county of Romania registered in Regional Center for Monitoring and Evaluation of HIV/AIDS of Craiova (demographics, symptoms, immunologic evaluation, TB type, TB related number of treatments) in order to identify risk factors for progression to active TB in this subset of patients.Material and Method: We perf...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Tuberculosis Source Type: research
Men who have sex with men (MSM) have high rates of infectious gastroenteritis, and infections with multidrug-resistant pathogens are common, according to new findings.Reuters Health Information
Source: Medscape Hiv-Aids Headlines - Category: Infectious Diseases Tags: Infectious Diseases News Source Type: news
Conclusions: Even though the mortality rates of all HIV and TB co-infection types have decreased recently, the overall trends in both incidence and prevalence rates of HIV-infected DS-TB and XDR-TB have been increasing since 1990. Efforts to control co-infection across drug resistance types should be continued and further strengthened. PMID: 31656655 [PubMed]
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research
A 25 year-old tuberculosis patient is treated at her home in Funafuti, the main island of Tuvalu in the South Pacific. Credit: UNDP Tuvalu/Aurélia Rusek.By External SourceUNITED NATIONS, Oct 17 2019 (IPS) A staggering 1.5 million people died from tuberculosis (TB) last year, the UN health agency said on Thursday, in an appeal for far greater funding and political support to eradicate the curable and preventable disease. Caused by the bacteria Mycobacterium tuberculosis, TB commonly causes persistent coughing, fatigue and weight loss. According to the World Health Organization (WHO) and its latest Global TB Report, a...
Source: IPS Inter Press Service - Health - Category: International Medicine & Public Health Authors: Tags: Global Headlines Health Poverty & SDGs Source Type: news
Tuberculosis (TB), which is estimated to be the deadliest infectious disease worldwide with ~1.6 million deaths yearly [1], is a clinical issue due to the "ancient" diagnostics and drugs currently available. If compared with the management of other highly prevalent infectious diseases, such as HIV/AIDS and hepatitis C virus infection, it is clear that the clinical approach for TB disease requires innovation, being still based on means with limited efficacy (e.g. treatment of multidrug-resistant TB; MDR-TB), and characterised by the denominator "long duration": conventional bacteriological diagnosis, the...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Editorials Source Type: research
ABSTRACT: Introduction: The mortality rate among tuberculosis patients (TB fatality) has been attributed to irregular chemotherapy, delay in diagnosis, multidrug resistance, and HIV coinfection. Objective: To analyze TB fatality rates by sex, clinical presentation and HIV coinfection in Campinas, S ão Paulo, Brazil. Methods: Cohorts of residents in the city of Campinas who either died during treatment for tuberculosis or had the disease confirmed after death were divided into three intervals: 2001-2003, 2004-2006, and 2007-2009. Data were obtained from the database of the Tuberculosis Surve illance System of the Uni...
Source: Revista Brasileira de Epidemiologia - Category: Epidemiology Source Type: research
CONCLUSIONS: Rifabutin should be available globally as a first-line rifamycin in HIV co-infected individuals and as a switch option in cases of rifampicin associated ADRs. Further studies are needed to ascertain the utility of rifabutin in rifampicin-resistant rifabutin-susceptible TB. PMID: 31318176 [PubMed - in process]
Source: Journal of the International AIDS Society - Category: Infectious Diseases Tags: J Int AIDS Soc Source Type: research
What do we know about the treatment success rate of bedaquiline in multidrug-resistant tuberculosis?Emerging Infectious Diseases
Source: Medscape Hiv-Aids Headlines - Category: Infectious Diseases Tags: Infectious Diseases Journal Article Source Type: news
Abstract Combination antiretroviral therapy has achieved dramatic reductions in the mortality and morbidity in people with HIV-1 infection. Darunavir (DRV) represents a most efficacious and well-tolerated protease inhibitor (PI) with high genetic barrier to the emergence of drug-resistant HIV-1. However, highly DRV-resistant variants have been reported in patients receiving long-term DRV-containing regimens. Here, we report three novel HIV-1 PIs (GRL-057-14, GRL-058-14, and GRL-059-14), all of which contain a P2-amino-substituted-bis-tetrahydrofuranylurethane (bis-THF) and a P2'-cyclopropyl-amino-benzothiazole (Cp...
Source: Antimicrobial Agents and Chemotherapy - Category: Microbiology Authors: Tags: Antimicrob Agents Chemother Source Type: research
Conclusion: Younger children are more likely to develop TB within a year of presentation whereas those who were near the adolescent age group were more likely to develop TB after 3 years of diagnosis of HIV. Thus, role of IPT in adolescents for 3 years at the time of diagnosis may not be useful as they tend to develop TB later on whereas IPT may be useful in the younger age group. With high incidence of MDR-TB, role of IPT in HIV-infected children in India needs to be re-assessed.
Source: Indian Journal of Sexually Transmitted Diseases - Category: Infectious Diseases Authors: Source Type: research
More News: European Medicines Agency (EMA) | HIV AIDS | Marketing | Multidrug Resistance | Students | Universities & Medical Training